- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
MHE Question of the Week: Which Was Your Favorite Superbowl Commercial?
Which of these was your favorite Super Bowl commercial?
We thought we’d take a break from serious healthcare topics this week and ask a just-for-fun question about Super Bowl ad preferences. We saw Pfizer's "Here's To Science." but as far as we know, no other healthcare companies advertised during last night’s game, which the Kansas City Chiefs won in overtime, much to the delight of a certain singer and her boyfriend. For lack of a big showing by healthcare companies, we selected some advertisers that are somewhat health and healthcare adjacent. And we added a couple of our favorites (those E*Trade babies get us every time).
What was your favorite Superbowl commercial?
We want to know what you’re thinking! Every Monday morning, the editors of Managed Healthcare Executive are posing a question to our readers about a timely issue in U.S. healthcare. We'll tally your answers and publish the results on Friday by 4 p.m. ET.
Have a suggestion for a Question for the Week? Please send it to Peter Wehrwein at pwehrwein@mjhlifesciences.com
Most Real-World Studies Report Positive Outcomes of Rituximab Use in Multiple Sclerosis
May 8th 2024Although several clinical trials have confirmed the safety and efficacy of rituximab in oncology and autoimmune disease, and even as off-label use in MS, real-world evidence is still necessary to help guide clinicians and managed care professionals in their treatment and coverage decision-making.
Read More
